Keros Therapeutics(US:KROS) Globenewswire·2026-03-04 21:01Core Insights - Keros Therapeutics, Inc. is focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family, with a business update and financial results for Q4 and the full year 2025 reported [1][2] Financial Performance - Keros reported a net loss of $23.5 million for Q4 2025, a significant improvement from a net loss of $46.0 million in Q4 2024. For the full year 2025, the company achieved a net income of $87.0 million compared to a net loss of $187.4 million in 2024 [4] - Total revenue for 2025 was $244.1 million, a substantial increase from $3.6 million in 2024, primarily driven by a license agreement with Takeda Pharmaceuticals [12] - Research and development expenses decreased to $17.9 million in Q4 2025 from $45.6 million in Q4 2024, and for the full year, expenses were $129.6 million compared to $173.6 million in 2024, mainly due to the transition of elritercept-related expenses to Takeda [5] - General and administrative expenses increased to $11.7 million in Q4 2025 from $10.7 million in Q4 2024, with full-year expenses at $46.8 million compared to $40.8 million in 2024, attributed to higher external expenses [6] - Cash and cash equivalents as of December 31, 2025, were $287.4 million, down from $559.9 million in 2024, primarily due to share repurchases and a cash tender offer [7] Corporate Developments - The company is advancing rinvatercept into a Phase 2 clinical trial for Duchenne muscular dystrophy (DMD) and is engaging regulators for a Phase 2 trial in amyotrophic lateral sclerosis (ALS) [2][8] - In February 2026, Keros appointed Charles Newton to its board of directors and promoted Esther Cho to Chief Legal Officer [8] Product Pipeline - Keros' lead product candidate, rinvatercept, is being developed for DMD and ALS, while elritercept is aimed at treating cytopenias in myelodysplastic syndrome and myelofibrosis [9]